Abstract:Herein, we developed a doxorubicin (Dox)-loaded and 4T1 cancer cell membrane-modified hydrogenated manganese oxide nanoparticles (mHMnO-Dox) to elicit systemic antitumor immune responses. The results revealed that mHMnO-Dox actively recognized tumor cells and then effectively delivered Dox into the cells. Upon entering tumor cells, the mHMnO-Dox underwent rapid degradation and abundant release of Mn<sup>2+</sup> and chemotherapeutic drugs. The released Mn<sup>2+</sup> not only catalysed a Fenton-type reaction to produce excessive reactive oxygen species (ROS) but also activated the cGAS-STING pathway to boost dendritic cell (DC) maturation. This process increased cytotoxic T lymphocyte infiltration as well as natural killer cell recruitment into the tumor site. In addition, the released Dox could contribute to a chemotherapeutic effect, while activating DC cells and subsequently intensifying immune responses through immunogenic cell death (ICD) of tumor cells. Consequently, the mHMnO-Dox suppressed the primary and distal tumor growth and inhibited tumor relapse and metastasis, as well as prolonged the lifespan of tumor-bearing mice. Thus, the mHMnO-Dox multimodally activated DC cells to demonstrate synergistic antitumor activity, which was mediated via the activation of the cGAS-STING signalling pathway to regulate tumor microenvironment, ICD-mediated immunotherapy and ROS-mediated CDT. These findings suggest the therapeutic potential of mHMnO-Dox in cancer immunotherapy. STATEMENT OF SIGNIFICANCE: A cancer cell membrane-camouflaged hydrogenated mesoporous manganese oxide (mHMnO) has been developed as a cGAS-STING agonist and ICD inducer. The mHMnO effectively induced abundance of ROS production in cancer cells, which caused cancer cell death and then promoted DC maturation via tumour-associated antigen presentation. Meanwhile, the mHMnO significantly activated cGAS-STING pathway to facilitate DC maturation and cytotoxic T lymphocyte infiltration as well as natural killer cell recruitment, which further enhanced tumour immune response. In addition, the combination of the mHMnO and Dox could synergistically promote tumour ICD and then multimodally induce DC maturation, achieving an enhanced CIT. Overall, this study provides a potential strategy to design novel immunologic adjuvant for enhanced CIT.

Pam 3 CSK 4 -CDG SF Augments Antitumor Immunotherapy by Synergistically Activating TLR1/2 and STING

Pam3CSK4-CDGSF Augments Antitumor Immunotherapy by Synergistically Activating TLR1/2 and STING

Co-delivery of Phagocytosis Checkpoint Silencer and Stimulator of Interferon Genes Agonist for Synergetic Cancer Immunotherapy

A Bi-Adjuvant Nanovaccine Amplifying STING Activation for Cancer Immunotherapy

STING Activator c-di-GMP-Loaded Mesoporous Silica Nanoparticles Enhance Immunotherapy Against Breast Cancer

Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine

STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation

Chitosan-based nano-micelles for potential anti-tumor immunotherapy: Synergistic effect of cGAS-STING signaling pathway activation and tumor antigen absorption

Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles

Dual-responsive PEG-lipid Polyester Nanoparticles for Sirna and Vaccine Delivery Elicit Anti-Cancer Immune Responses by Modulating Tumor Microenvironment

Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity

Ionizable STING-Activating Nanoadjuvants Enhance Tumor Immunogenicity and Potentiate Immunotherapy Efficacy in Solid Tumors

A homologous-targeting cGAS-STING agonist multimodally activates dendritic cells for enhanced cancer immunotherapy

A Trinity STING-activating Nanoparticle Harnesses Cancer Cell STING Machinery for Enhanced Immunotherapy

TLR9 plus STING Agonist Adjuvant Combination Induces Potent Neopeptide T Cell Immunity and Improves Immune Checkpoint Blockade Efficacy in a Tumor Model

Co-delivery of doxorubicin and STING agonist cGAMP for enhanced antitumor immunity

Apoptotic Body-Mediated Intracellular Delivery Strategy for Enhanced STING Activation and Improved Tumor Immunogenicity

The Self-Adjuvant Heterocyclic Lipid Nanoparticles Encapsulated with Vaccine and STAT3 Sirna Boost Cancer Immunotherapy Through DLN-targeted and STING Pathway

Acid‐Ionizable Iron Nanoadjuvant Augments STING Activation for Personalized Vaccination Immunotherapy of Cancer

Assembly of 2′,3′-Cyclic Guanosine Monophosphate-Adenosine Monophosphate and Their Spontaneous Intracellular Disassembly for Enhanced Antitumor Immunity Via Natural STING Pathway Activation

Regulating the Surface Topography of CpG Nanoadjuvants Via Coordination-Driven Self-Assembly for Enhanced Tumor Immunotherapy.